An elevated body mass index does not reduce survival after esophagectomy for cancer

Marcovalerio Melis, Jill M. Weber, James Mcloughlin, Erin M. Siegel, Sarah Hoffe, Ravi Shridhar, Kiran K. Turaga, George Dittrick, E. Michelle DittrickDean, Richard C. Karl, Kenneth L. Meredith

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background. Incidences of esophageal cancer and obesity are both rising in the United States. The aim of this study was to determine the influence of elevated body mass index on outcomes after esophagectomy for cancer. Methods. Overall and disease-free survivals in obese (BMI ≥ 30), overweight (BMI 25-29), and normal-weight (BMI 20-24) patients undergoing esophagectomy constituted the study end points. Survivals were calculated by the Kaplan-Meier method, and differences were analyzed by log rank method. Results. The study included 166 obese, 176 overweight, and 148 normal-weight patients. These three groups were similar in terms of demographics and comorbidities, with the exception of younger age (62.5 vs. 66.2 vs. 65.3 years, P = 0.002), and higher incidence of diabetes (23.5 vs. 11.4 vs. 10.1%, P = 0.001) and hiatal hernia (28.3 vs. 14.8 vs. 20.3%, P = 0.01) in obese patients. Rates of adenocarcinoma histology were higher in obese patients (90.8 vs. 90.9 vs. 82.5%, P = 0.03). Despite similar preoperative stage, obese patients were less likely to receive neoadjuvant treatment (47.6 vs. 54.5 vs. 66.2%, P = 0.004). Response to neoadjuvant treatment, type of surgery performed, extent of lymphadenectomy, rate of R0 resections, perioperative complications, and administration of adjuvant chemotherapy were not influenced by BMI. At a median follow-up of 25 months, 5-year overall and disease-free survivals were longer in obese patients (respectively, 48, 41, 34%, P = 0.01 and 48, 44, 34%, P = 0.01). Conclusions. In our experience, an elevated BMI did not reduce overall and disease-free survivals after esophagectomy for cancer.

Original languageEnglish (US)
Pages (from-to)824-831
Number of pages8
JournalAnnals of Surgical Oncology
Volume18
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Esophagectomy
Body Mass Index
Survival
Disease-Free Survival
Neoplasms
Neoadjuvant Therapy
Weights and Measures
Hiatal Hernia
Incidence
Adjuvant Chemotherapy
Esophageal Neoplasms
Lymph Node Excision
Comorbidity
Histology
Adenocarcinoma
Obesity
Demography

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Melis, M., Weber, J. M., Mcloughlin, J., Siegel, E. M., Hoffe, S., Shridhar, R., ... Meredith, K. L. (2011). An elevated body mass index does not reduce survival after esophagectomy for cancer. Annals of Surgical Oncology, 18(3), 824-831. https://doi.org/10.1245/s10434-010-1336-1

An elevated body mass index does not reduce survival after esophagectomy for cancer. / Melis, Marcovalerio; Weber, Jill M.; Mcloughlin, James; Siegel, Erin M.; Hoffe, Sarah; Shridhar, Ravi; Turaga, Kiran K.; Dittrick, George; DittrickDean, E. Michelle; Karl, Richard C.; Meredith, Kenneth L.

In: Annals of Surgical Oncology, Vol. 18, No. 3, 01.03.2011, p. 824-831.

Research output: Contribution to journalArticle

Melis, M, Weber, JM, Mcloughlin, J, Siegel, EM, Hoffe, S, Shridhar, R, Turaga, KK, Dittrick, G, DittrickDean, EM, Karl, RC & Meredith, KL 2011, 'An elevated body mass index does not reduce survival after esophagectomy for cancer', Annals of Surgical Oncology, vol. 18, no. 3, pp. 824-831. https://doi.org/10.1245/s10434-010-1336-1
Melis, Marcovalerio ; Weber, Jill M. ; Mcloughlin, James ; Siegel, Erin M. ; Hoffe, Sarah ; Shridhar, Ravi ; Turaga, Kiran K. ; Dittrick, George ; DittrickDean, E. Michelle ; Karl, Richard C. ; Meredith, Kenneth L. / An elevated body mass index does not reduce survival after esophagectomy for cancer. In: Annals of Surgical Oncology. 2011 ; Vol. 18, No. 3. pp. 824-831.
@article{4a07224f59a8470a8f844fe3dd0aa4e3,
title = "An elevated body mass index does not reduce survival after esophagectomy for cancer",
abstract = "Background. Incidences of esophageal cancer and obesity are both rising in the United States. The aim of this study was to determine the influence of elevated body mass index on outcomes after esophagectomy for cancer. Methods. Overall and disease-free survivals in obese (BMI ≥ 30), overweight (BMI 25-29), and normal-weight (BMI 20-24) patients undergoing esophagectomy constituted the study end points. Survivals were calculated by the Kaplan-Meier method, and differences were analyzed by log rank method. Results. The study included 166 obese, 176 overweight, and 148 normal-weight patients. These three groups were similar in terms of demographics and comorbidities, with the exception of younger age (62.5 vs. 66.2 vs. 65.3 years, P = 0.002), and higher incidence of diabetes (23.5 vs. 11.4 vs. 10.1{\%}, P = 0.001) and hiatal hernia (28.3 vs. 14.8 vs. 20.3{\%}, P = 0.01) in obese patients. Rates of adenocarcinoma histology were higher in obese patients (90.8 vs. 90.9 vs. 82.5{\%}, P = 0.03). Despite similar preoperative stage, obese patients were less likely to receive neoadjuvant treatment (47.6 vs. 54.5 vs. 66.2{\%}, P = 0.004). Response to neoadjuvant treatment, type of surgery performed, extent of lymphadenectomy, rate of R0 resections, perioperative complications, and administration of adjuvant chemotherapy were not influenced by BMI. At a median follow-up of 25 months, 5-year overall and disease-free survivals were longer in obese patients (respectively, 48, 41, 34{\%}, P = 0.01 and 48, 44, 34{\%}, P = 0.01). Conclusions. In our experience, an elevated BMI did not reduce overall and disease-free survivals after esophagectomy for cancer.",
author = "Marcovalerio Melis and Weber, {Jill M.} and James Mcloughlin and Siegel, {Erin M.} and Sarah Hoffe and Ravi Shridhar and Turaga, {Kiran K.} and George Dittrick and DittrickDean, {E. Michelle} and Karl, {Richard C.} and Meredith, {Kenneth L.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1245/s10434-010-1336-1",
language = "English (US)",
volume = "18",
pages = "824--831",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - An elevated body mass index does not reduce survival after esophagectomy for cancer

AU - Melis, Marcovalerio

AU - Weber, Jill M.

AU - Mcloughlin, James

AU - Siegel, Erin M.

AU - Hoffe, Sarah

AU - Shridhar, Ravi

AU - Turaga, Kiran K.

AU - Dittrick, George

AU - DittrickDean, E. Michelle

AU - Karl, Richard C.

AU - Meredith, Kenneth L.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background. Incidences of esophageal cancer and obesity are both rising in the United States. The aim of this study was to determine the influence of elevated body mass index on outcomes after esophagectomy for cancer. Methods. Overall and disease-free survivals in obese (BMI ≥ 30), overweight (BMI 25-29), and normal-weight (BMI 20-24) patients undergoing esophagectomy constituted the study end points. Survivals were calculated by the Kaplan-Meier method, and differences were analyzed by log rank method. Results. The study included 166 obese, 176 overweight, and 148 normal-weight patients. These three groups were similar in terms of demographics and comorbidities, with the exception of younger age (62.5 vs. 66.2 vs. 65.3 years, P = 0.002), and higher incidence of diabetes (23.5 vs. 11.4 vs. 10.1%, P = 0.001) and hiatal hernia (28.3 vs. 14.8 vs. 20.3%, P = 0.01) in obese patients. Rates of adenocarcinoma histology were higher in obese patients (90.8 vs. 90.9 vs. 82.5%, P = 0.03). Despite similar preoperative stage, obese patients were less likely to receive neoadjuvant treatment (47.6 vs. 54.5 vs. 66.2%, P = 0.004). Response to neoadjuvant treatment, type of surgery performed, extent of lymphadenectomy, rate of R0 resections, perioperative complications, and administration of adjuvant chemotherapy were not influenced by BMI. At a median follow-up of 25 months, 5-year overall and disease-free survivals were longer in obese patients (respectively, 48, 41, 34%, P = 0.01 and 48, 44, 34%, P = 0.01). Conclusions. In our experience, an elevated BMI did not reduce overall and disease-free survivals after esophagectomy for cancer.

AB - Background. Incidences of esophageal cancer and obesity are both rising in the United States. The aim of this study was to determine the influence of elevated body mass index on outcomes after esophagectomy for cancer. Methods. Overall and disease-free survivals in obese (BMI ≥ 30), overweight (BMI 25-29), and normal-weight (BMI 20-24) patients undergoing esophagectomy constituted the study end points. Survivals were calculated by the Kaplan-Meier method, and differences were analyzed by log rank method. Results. The study included 166 obese, 176 overweight, and 148 normal-weight patients. These three groups were similar in terms of demographics and comorbidities, with the exception of younger age (62.5 vs. 66.2 vs. 65.3 years, P = 0.002), and higher incidence of diabetes (23.5 vs. 11.4 vs. 10.1%, P = 0.001) and hiatal hernia (28.3 vs. 14.8 vs. 20.3%, P = 0.01) in obese patients. Rates of adenocarcinoma histology were higher in obese patients (90.8 vs. 90.9 vs. 82.5%, P = 0.03). Despite similar preoperative stage, obese patients were less likely to receive neoadjuvant treatment (47.6 vs. 54.5 vs. 66.2%, P = 0.004). Response to neoadjuvant treatment, type of surgery performed, extent of lymphadenectomy, rate of R0 resections, perioperative complications, and administration of adjuvant chemotherapy were not influenced by BMI. At a median follow-up of 25 months, 5-year overall and disease-free survivals were longer in obese patients (respectively, 48, 41, 34%, P = 0.01 and 48, 44, 34%, P = 0.01). Conclusions. In our experience, an elevated BMI did not reduce overall and disease-free survivals after esophagectomy for cancer.

UR - http://www.scopus.com/inward/record.url?scp=79955718048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955718048&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-1336-1

DO - 10.1245/s10434-010-1336-1

M3 - Article

VL - 18

SP - 824

EP - 831

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 3

ER -